Mandate

Vinge advises Capio in conjunction with its acquisition of PR Vård

Vinge is advising Capio in connection with its acquisition of all shares in PR Vård Hemsjukvåd AB and PR Vård Mottagning AB.

PR Vård conducts home healthcare operations in five out of eight primary health areas in Stockholm as well as one surgery for children and young people and one healthcare surgery in Södermalm. PR Vård has 600 employees and performs approximately 1 million home healthcare visits per year. The acquisition is subject to approval by the Swedish Competition Authority.

Vinge’s team consisted of partner Anders Strid and Jenny Sandlund (project manager), Victoria Gunnerek (public procurement), Adam Löwenstein (tenancy law), Alexander Lindeberg (IT/GDPR), Anna Ståhlklo (employment law), Fredrik Löwenklou (M&A) as well as Anna Palmérus (competition law).

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024